Sanofi S.A., FR0000120578

Sanofi announces Regeneron alliance expansion and Sanofi stock costs EUR 71.12

Published on 10/03/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi expands its Regeneron alliance with four antibodies. Sanofi stock costs EUR 71.12 in weekend trading on October 3, 2026 versus EUR 71.10 at the Xetra close.

Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi announced an expansion of its antibody collaboration with Regeneron on October 1, 2026, adding four long-acting immunology antibodies to the alliance, according to the company’s press release. Sanofi stock costs EUR 71.12 in weekend trading at Lang & Schwarz on October 3, 2026, at 10:25 a.m. CEST, up plus 0.03 percent versus the EUR 71.10 close at Lang & Schwarz on October 2, 2026.

Weekend trading

The Lang & Schwarz quote shows a bid of EUR 71.10 and an ask of EUR 71.13. The price is quoted in euros while Xetra remains closed for the October 3, 2026 trading session. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Sanofi stock.

Expanded Regeneron alliance

Under the expanded agreement, Sanofi and Regeneron will co-develop and co-commercialize four new long-acting antibodies targeting interleukin-13, an interleukin-4 and interleukin-13 bispecific, interleukin-4 and the interleukin-4 receptor alpha. Regeneron’s REGN20423 is in a phase 1 clinical study for atopic dermatitis, while the other three antibodies are expected to enter clinical studies in 2027, the company said.

Regeneron will receive a $1 billion upfront payment from Sanofi, with potential development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercialization costs and split future profits from the potential products equally. The existing Dupixent profit-sharing agreement will not change.